GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

NCT00896519 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
BIOLOGICAL: sargramostim
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: prednisone
DRUG: vincristine sulfate
GENETIC: gene expression analysis
GENETIC: gene rearrangement analysis
GENETIC: polymerase chain reaction
OTHER: R-CHOP regimen
OTHER: laboratory biomarker analysis

Sponsor

French Innovative Leukemia Organisation